SCHEMBL23529311

SCHEMBL23529311

COc1c(C(N)=O)ccc2c1nc(-c1ccccc1-c1nn[nH]n1)n2CCn1c(-c2ccccc2-c2nn[nH]n2)nc2c(OC)c(C(N)=O)ccc21

nearest known ligand 0.49

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 5/20 0.42
AGTR2 P50052 3/20 0.42
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24801693 0.88 PKN1 (0.38)
SCHEMBL29948114 0.88 PKN1 (0.38)
SCHEMBL23529335 0.88 XDH (0.39) AGTR1
SCHEMBL23529388 0.88 IDO1 (0.39) AGTR1
SCHEMBL29948221 0.87 ACSS2 (0.39)
SCHEMBL23529329 0.87 PKN1 (0.37)
SCHEMBL23529304 0.87 ACSS2 (0.39)
SCHEMBL23552631 0.84 PKN1 (0.34)
SCHEMBL29948157 0.84 PKN1 (0.34)
SCHEMBL24801607 0.83 NAE1 (0.35) AGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132112-A1 COMPOUNDS CTXT PTY LTD (AU) 2026-05-14 US claimed
EP-4077318-B1 BENZIMIDAZOLE DIMERS AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-10-15 EP claimed
US-12415785-B2 Compound modulators of sting CTXT PTY LTD (AU) 2025-09-16 US claimed
CN-114981265-B Compounds of formula (I) CTXT私人有限公司 2025-01-03 CN claimed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 US claimed
EP-4077318-A1 COMPOUNDS CTXT PTY LTD (AU) 2022-10-26 EP claimed
CN-114981265-A Compound (I) CTXT私人有限公司 2022-08-30 CN claimed
WO-2021119753-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2021-06-24 WO claimed
EP-4077318-B1 BENZIMIDAZOLE DIMERS AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-10-15 EP disclosed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 US disclosed
WO-2022266711-A1 SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS Aculeus Therapeutics Pty Ltd (AU) 2022-12-29 WO disclosed
WO-2022266711-A1 SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS Aculeus Therapeutics Pty Ltd (AU) 2022-12-29 WO disclosed
EP-4077318-A1 COMPOUNDS CTXT PTY LTD (AU) 2022-10-26 EP disclosed
WO-2021119753-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415785-B2 Compound modulators of sting STING1, IRF3, MAVS AGTR1 2978/4885AGTR2 3071/4885GAA 572/4885
US-20260132112-A1 COMPOUNDS STING1, IRF3, CGAS AGTR1 1490/4885AGTR2 2167/4885GAA 2456/4885
US-20230062932-A1 COMPOUNDS STING1, IRF3, MAVS AGTR1 2120/4885AGTR2 2226/4885GAA 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.